Dino Paolucci - Pharmacom Biovet VP of D Mecatronics and Director
| PHMB Stock | USD 0.0001 0.00 0.00% |
Director
Dino Paolucci is VP of D Mecatronics and Director of Pharmacom Biovet
| Address | 6040-A Six Forks Road, Raleigh, NC, United States, 27609 |
| Phone | 919 604 4887 |
Similar Executives
| Found 9 records | DIRECTOR Age | ||
| Wayne Riley | HCA Holdings | 61 | |
| Robert Dennis | HCA Holdings | 67 | |
| Norleidy Hernandez | IMAC Holdings | N/A | |
| Meg Crofton | HCA Holdings | 67 | |
| NancyAnn DeParle | HCA Holdings | 64 | |
| William Frist | HCA Holdings | 51 | |
| Charles Holliday | HCA Holdings | 73 | |
| Michael Michelson | HCA Holdings | 69 | |
| Roy Youngblood | P3 Health Partners | N/A | |
Pharmacom Biovet Management Team
Elected by the shareholders, the Pharmacom Biovet's board of directors comprises two types of representatives: Pharmacom Biovet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharmacom. The board's role is to monitor Pharmacom Biovet's management team and ensure that shareholders' interests are well served. Pharmacom Biovet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharmacom Biovet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve York, VP of Operations and Marketing and Director | ||
| Ira Frohman, President, Secretary, Treasurer and Director | ||
| Dino Paolucci, VP of D Mecatronics and Director |
Pharmacom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharmacom Biovet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.08 M | ||||
| Net Income | (556.18 K) | ||||
| Total Debt | 61.54 K | ||||
| Beta | 168.8 | ||||
| Market Capitalization | 1.08 M | ||||
| Total Asset | 112.36 K | ||||
| Retained Earnings | (19.05 M) | ||||
| Working Capital | (29 K) | ||||
| Current Liabilities | 29 K | ||||
| Net Asset | 112.36 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pharmacom Biovet offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmacom Biovet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacom Biovet Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacom Biovet Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharmacom Biovet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. If investors know Pharmacom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmacom Biovet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pharmacom Biovet is measured differently than its book value, which is the value of Pharmacom that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmacom Biovet's value that differs from its market value or its book value, called intrinsic value, which is Pharmacom Biovet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmacom Biovet's market value can be influenced by many factors that don't directly affect Pharmacom Biovet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharmacom Biovet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharmacom Biovet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.